Approach to managing patients with nail psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue SUPPL. 1, 2009, Pages 15-21

  Reich, K ^a  

^a DERMATOLOGIKUM HAMBURG   (Germany)

Author keywords

Biologic therapy; Infliximab; Nail psoriasis; Quality of life; Treatment

Indexed keywords

BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DITHRANOL; ETRETINATE; FLUOROURACIL; GLUCOCORTICOID; INFLIXIMAB; PLACEBO; RETINOID TAZOROTENE; TRIAMCINOLONE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HUMAN; HYPERKERATOSIS; NAIL; NAIL DISEASE; NAIL PSORIASIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; SKIN ATROPHY; SKIN IRRITATION; STRIA; TELANGIECTASIA; THERAPY EFFECT; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; NAIL DISEASES; PSORIASIS; QUALITY OF LIFE;

EID: 69049113992     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03364.x     Document Type: Review

References (39)

1. Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician 2000 61 : 725 733.
2. Jiaravuthisan MM, Sasseville D, Vender RB et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007 57 : 1 27.
3. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 407.
4. Kreuger GG, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 137 : 280 284.
5. Lebwohl M. Psoriasis. Lancet 2003 361 : 1197 1204.
6. Gladman DD, Antoni C, Mease P et al. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis 2005 64 : 14 17.
7. Kyle S, Chandler D, Griffiths CEM et al. Guideline for anti-TNF-α therapy in psoriatic arthritis. Rheumatology 2005 44 : 390 397.
8. Leung YY, Tam LS, Kun EW, Li EK. Psoriatic arthritis as a distinct disease entity. J Postgrad Med 2007 53 : 63 71.
9. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008 216 : 366 372.
10. Williamson L, Dalbeth N, Dockerty JL et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology 2004 43 : 790 794.
11. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007 20 : 60 67.
12. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 1999 26 : 1752 1756.
13. Jones SM, Armas JB, Cohen MG et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994 33 : 834 839.
14. de Jong EM, Seegers BA, Gulinck MK et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996 193 : 300 303.
15. Van Laborde S, Scher RK. Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis. A review of the literature. Dermatol Clin 2000 18 : 37 46.
16. Wilson FC, Icen M, Crowson CS et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009 61 : 233 239.
17. Rich P, Griffiths CE, Reich K et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008 58 : 224 231.
18. Baran RL. A nail psoriasis severity index. Br J Dermatol 2004 150 : 568 569.
19. Cannavò SP, Guarneri F, Vaccaro M et al. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003 206 : 153 156.
20. Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003 49 : 206 212.
21. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 216.
22. Tosti A, Piraccini BM, Cameli N et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998 139 : 655 659.
23. Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002 82 : 140.
24. de Jong EM. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 1999 199 : 313 318.
25. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001 68 : 355 358.
26. Yamamoto T. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998 25 : 231 233.
27. de Berker DAR, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998 138 : 90 95.
28. Handfield-Jones SE, Boyle J, Harman RRM. Local PUVA treatment for nail psoriasis. Br J Dermatol 1987 116 : 280 281.
29. Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980 116 : 1023 1024.
30. Mahrle G, Schultze HJ, Färber L et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement in skin, nail, and joint involvement. J Am Acad Dermatol 1995 32 : 78 88.
31. Feliciani C, Zampetti A, Forleo P et al. Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg 2004 8 : 122 125.
32. Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004 151 (Suppl 3 17.
33. Gianetti A et al. (Title) Abstract FC08-7, spring EADV 2008 (CRYSTEL).
34. Van den Bosch F, Reece R, Behrens F et al. Clinically important nail psoriasis improvements are achieved with adalimumab (Humira®): results from a large open-label prospective study (STEREO). Ann Rheum Dis 2007 66 (Suppl. II 421.
35. Martins G et al. (Title) WCD 2007 Poster 5279.
36. Cassetty CT, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: a small case series. J Am Acad Dermatol 2005 52 : 1101 1102.
37. Parrish CA, Sobera JO, Robbins CM et al. Alafacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 2006 5 : 339 340.
38. Reich K, Nestle FO, Papp K, the EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 1374.
39. Rigopoulos D, Gregoriou S, Stratigos A et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008 159 : 453 456.